PF-07059013: A non-covalent hemoglobin modulator favorably impacts disease state in a mouse model of sickle cell disease

Affiliations

• ¹ Rare Disease Research Unit, Pfizer Worldwide Research, Development, and Medical, Cambridge, Massachusetts, USA.
• ² Primary Pharmacology Group, Pfizer Medicine Design, Pfizer Worldwide Research, Development and Medical, Groton, Connecticut, USA.
• ³ Discovery Sciences, Pfizer Worldwide Research, Development and Medical, Groton, Connecticut, USA.
• ⁴ Pharmacokinetics, Dynamics, Metabolism, Pfizer Medicine Design, Pfizer Worldwide Research, Development and Medical, Groton, Connecticut, USA.
• ⁵ Pfizer Medicine Design, Pfizer Worldwide Research, Development and Medical, Groton, Connecticut, USA.